Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer

被引：184
|
作者：
Amatu, A. [1 ]
Sartore-Bianchi, A. [1 ,2 ]
Bencardino, K. [1 ]
Pizzutilo, E. G. [1 ,2 ]
Tosi, F. [1 ,2 ]
Siena, S. [1 ,2 ]
机构：
[1] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Dept Hematol & Oncol, Piazza Osped Maggiore 3, I-20162 Milan, Italy
[2] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
基金：
欧盟地平线“2020”;
关键词：
TRK; tropomyosin receptor kinase; NTRK gene fusions; TRK fusion cancer; NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; NEUROTROPHIC FACTOR; MESOBLASTIC NEPHROMA; TARGETED THERAPY; CONGENITAL INSENSITIVITY; INHIBITOR ENTRECTINIB; PROTOONCOGENE PRODUCT; ACQUIRED-RESISTANCE; HIGH-FREQUENCY;
D O I：
10.1093/annonc/mdz383
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The tropomyosin receptor kinase (TRK) family of receptor tyrosine kinases are encoded by NTRK genes and have a role in the development and normal functioning of the nervous system. Since the discovery of an oncogenic NTRK gene fusion in colorectal cancer in 1986, over 80 different fusion partner genes have been identified in a wide array of adult and paediatric tumours, providing actionable targets for targeted therapy. This review describes the normal function and physiology of TRK receptors and the biology behind NTRK gene fusions and how they act as oncogenic drivers in cancer. Finally, an overview of the incidence and prevalence of NTRK gene fusions in various types of cancers is discussed.
引用
收藏
页码：VIII5 / VIII15
页数：11
相关论文
共 50 条
  • [41] CLINICAL OUTCOMES OF PATIENTS WITH NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION CANCER TREATED WITH NON-TROPOMYOSIN RECEPTER KINASE INHIBITORS: A SYSTEMATIC LITERATURE REVIEW
    Pan, X.
    Jiao, X.
    Ruiz, K.
    Stewart, F.
    Kistler, K.
    Patel, R.
    Zong, J.
    Bernard-Gauthier, V
    VALUE IN HEALTH, 2022, 25 (12) : S50 - S50
  • [42] The role of the Neurotrophic tyrosine kinase receptor-1 gene (NTRK-1) in the progression of breast cancer
    Hussan, W. H.
    Sharma, V. S.
    JOURNAL OF PATHOLOGY, 2023, 261 : S36 - S36
  • [43] Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive tumors: a historical cohort analysis
    Lemelle, Lauriane
    Guillemot, Delphine
    Hermann, Anne-Laure
    Gauthier, Arnaud
    Carton, Matthieu
    Corradini, Nadege
    Rome, Angelique
    Berlanga, Pablo
    Jourdain, Anne
    Cardine, Aude Marie
    Jannier, Sarah
    Boutroux, Helene
    Defachelles, Anne Sophie
    Aerts, Isabelle
    Geoerger, Birgit
    Karanian, Marie
    Doz, Francois
    Brisse, Herve J.
    Schleiermacher, Gudrun
    Delattre, Olivier
    Pierron, Gaelle
    Orbach, Daniel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (08) : 865 - 874
  • [44] Design, synthesis and evaluate of indazolylaminoquinazoline derivatives as potent Tropomyosin receptor kinase (TRK) inhibitors
    Xu, Yunsheng
    Zhao, Wei
    Zhang, Xinyi
    Yu, Xihua
    Chen, Yinbo
    Wang, Zhenghai
    Chu, Yong
    Zhu, Xueyan
    Zhang, Peng
    BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 99
  • [45] ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION SOLID TUMORS
    Tabatabai, Ghazaleh
    Trent, Jonathan
    Novello, Silvia
    Passiglia, Francesco
    Burcoveanu, Domnita-Ileana
    Norenberg, Ricarda
    Laetsch, Theodore
    NEURO-ONCOLOGY, 2023, 25
  • [46] NTRK (NEUROTROPHIC TYROSINE RECEPTOR KINASE) FUSIONS IN GLIOMA PATIENTS: A PROMISING MOLECULAR TARGET?
    Vernadou, Anastasia
    Argyrakos, Theodoros
    Papadopoulou, Eirini
    Rigakos, Georgios
    Tsoukalas, Konstantinos
    Labropoulos, Stefanos
    Avgoustidou, Maria
    Razis, Evangelia
    NEURO-ONCOLOGY, 2021, 23 : 13 - 13
  • [47] Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion Cancer
    Rieke, D. T.
    Hong, D. S.
    Drilon, A.
    Tan, D. S.
    Lin, J.
    Kummar, S.
    McDermott, R.
    Berlin, J.
    Italiano, A.
    Lassen, U. N.
    Leyvraz, S.
    Tahara, M.
    Norenberg, R.
    Burcoveanu, D. -I.
    Brega, N.
    Shen, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 142 - 143
  • [48] EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE CANCER: AN EXPANDED DATASET
    Koga, Yuhki
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [49] EFFICACY AND SAFETY OF LAROTRECTINIB IN PAEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER: AN EXTENDED FOLLOW-UP
    Zwaan, C. Michel
    Van Tilburg, Cornelis
    Doz, Francois
    Albert, Catherine
    Blattmann, Claudia
    Geoerger, Birgit
    Dubois, Steven
    Federman, Noah
    Mascarenhas, Leo
    Nagasubramanian, Rama
    Pappo, Alberto
    Watt, Tanya
    Norenberg, Ricarda
    Dima, Laura
    De la Cuesta, Esther
    Laetsch, Theodore
    Xu, Ruihua
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S324 - S325
  • [50] Targeting tropomyosin receptor kinase for cancer therapy
    Miao, Qi
    Ma, Kun
    Chen, Dong
    Wu, Xiaoxing
    Jiang, Sheng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 175 : 129 - 148
12345